Calcific uraemic arteriolopathy (CUA), is a devastating complication seen in patients with chronic kidney disease (CKD). Despite an increasing awareness and incidence worldwide, there has been little progress regarding effective therapies. Sodium thiosulfate (STS) continues to prove a controversial topic in the literature and yet is used regularly in some renal units due to a lack of better options. Aside from case reports, there is no published literature looking at CUA in the New Zealand CKD population, which has a high prevalence of CKD in indigenous Māori patients.
No takes yet. Share an insight, caveat, or question.
Devathasan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: